Category: Client Objectives

Client Objectives

New Microneedle Can Obliterate Spider Veins in One Sesson

A new microneedle device—the Given Needle—may help eradicate spider veins with one treatment, a new study shows.

Client Objectives

FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Toxin Application

Agency requests additional manufacturing information and does not cite safety or efficacy concerns or require new clinical studies.

Client Objectives

New triLIFT 2.0 System Targets Muscle Layer in Aesthetic Treatments

Lumenis has introduced triLIFT 2.0, a new platform that combines muscle stimulation and skin treatment technologies to address facial and body aging by targeting both underlying muscle structure and dermal quality.

Aesthetics

Oncoplastic Breast Surgery Program Receives Center of Excellence Designation

The hospital has been named the world’s first Center of Excellence in oncoplastic breast surgery, recognizing its long-running program that integrates breast cancer removal and reconstruction into a single procedure.

Dermatology

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Vitiligo

If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, according to the company.

Rejuvenation

Survey Maps Facial Aesthetic Concerns After GLP-1–Associated Weight Loss

A national survey shows how GLP-1–associated weight loss is driving facial volume loss, laxity, and wrinkles—and why fillers and neuromodulators anchor treatment for this growing patient group. Plastic Surgery Practice talks to one of the study's authors to break down the findings and what they mean for treatment planning in today’s aesthetic practice.